Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

AIMS: The EVOLVE FHU trial demonstrated non-inferiority of six-month late loss with two dose formulations of SYNERGY, a novel bioabsorbable polymer everolimus-eluting stent (EES) compared with the durable polymer PROMUS Element (PE) EES. The current analysis describes the six-month IVUS and clinical results through two years from the EVOLVE FHU trial. METHODS AND RESULTS: EVOLVE recruited 291 patients from 29 centres. At six months, IVUS-assessed in-stent net volume obstruction was 3.40 ± 5.06% for PROMUS Element (PE) vs. 2.68 ± 4.60% for SYNERGY (p=0.34) and 3.09 ± 4.29% for SYNERGY ½ dose (p=0.68 vs. PE). There were no significant differences between groups for any other measured IVUS parameter including resolved, persistent, and late-acquired incomplete stent apposition (ISA). At two years, target lesion failure (TLF) was 6.1% for PE vs. 5.5% for SYNERGY (p=0.87) and 5.2% for SYNERGY ½ dose (p=0.81). There were no significant differences between groups for cardiac death, repeat revascularisation, MI or stent thrombosis through two years. CONCLUSIONS: At six months, everolimus delivered from an ultrathin bioabsorbable abluminal polymer resulted in equivalent net volume obstruction and ISA compared with a permanent polymer EES. There were no significant differences between PE and either SYNERGY stent for any major cardiac endpoint through two years. Clinical trials number: NCT01135225.

Original publication

DOI

10.4244/EIJV9I3A52

Type

Journal article

Journal

EuroIntervention

Publication Date

07/2013

Volume

9

Pages

308 - 315

Keywords

Australia, Cardiovascular Agents, Chi-Square Distribution, Coated Materials, Biocompatible, Coronary Angiography, Coronary Artery Disease, Coronary Restenosis, Coronary Thrombosis, Coronary Vessels, Drug-Eluting Stents, Europe, Everolimus, Humans, Kaplan-Meier Estimate, Myocardial Infarction, New Zealand, Percutaneous Coronary Intervention, Polymers, Predictive Value of Tests, Prosthesis Design, Risk Factors, Sirolimus, Time Factors, Treatment Outcome, Ultrasonography, Interventional